Assessment of ovarian tumor marker CA-125 during radiotherapy course

Abstract

The antigen secretion by ovarian cancer (CA-125) has been assessed using Radio Immune Assay (RIA) technique among a hundred ovarian cancer patients who received radiotherapy course as radical treatment. The study revealed that, the ovarian cancer commonly associated with the age groups of 30-40 years old taking a percent of 68 relative to other age groups and the antigen CA-125 does not has relation with aging. While the radiotherapy shows it is efficiency in management of ovarian cancer by reducing the antigen CA-125 level from 134 ± 13.3 U/ml to 5.5 ± 2.1 U/ml relative to normal level of CA-125 (35 U/ml). Also there is significant relationship between the cancer stage and the level of antigen CA-125 (R2=0.98).

Keywords

• Ovarian cancer
• Radiation therapy and tumor maker
• Radioimmuneassay

References

1. ACOG: American College of Obstetricians and Gynecologists, 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 100, 1413-1416.
2. American Cancer Society. Cancer Facts and Figures. (2012). Atlanta, GA.
3. Bast, R.C. Jr., Feeney, M., Lazarus, M., Nadler, L.M., Colvin, R.B., Knapp, R.C., 1981. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337.
4. Bast, R.C. Jr., Klug, T.L., ST. John, E., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 308, 883-887.
5. Bhattacharya, M., Chatterjee, S.K., Barlow, J.J., Fuji, H. 1982. Monoclonal antibodies recognizing Tumour-associated antigens of human ovar- ian mucinous cystadenocarcinomas. Cancer Res. 42, 1650-1654.
6. Canney, P.A., Moore M., Wilkinson, P.M., James, R.D., 1984. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Brth. J. Cancer. 50, 765-769.
7. Coussy, F., Chéreau, E., Daraï, E., Dhombres, F., Lotz, J.P., Rouzier, R., Selle, F., 2011. Interest of CA 125 level in management of ovarian can- cer. Gynecol. Obstet. Fertil. 39, 296-301.
8. Donaldson, E.S., Van Nagell, J.R., Pursell, S., 1980. Multiple biochemical markers on patients with gynaecologic malignancies. Cancer. 45, 948-953.

9. Goone Wardene, T.I., 2007. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 8, 813-821.
10. Gregory, P. Beehler., Manveen S., Julie, A. B., Barbara E. T., Susan, E. M., Kerry J. R., and Kirsten B. M., 2006. Risk of ovarian cancer associ- ated with BMI varies by menopausal status.J. Nutr. 136, 2881–2886.
11. Hogdall, E., 2008. Cancer antigen CA-125 and prognosis. Curr. Opin. Obstet. Gynecol. 20, 4-8.
12. Keys, A., Fidanza, F., Karvonen, M.J., Kimura, N., Taylor, H.L., 1972. Indices of relative weight and adiposity. J. Chronic. Dis. 25, 329-343.
13. Kramer, J.L., Greene, M.H., 2004. Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers. in: Gynecologic Cancer: Contro- versies in Management. Gershenson, D., Gore, M., McGuire, W., Quinn, M., Thomas, G., editors. Elsevier Science. pp. 327-340.
14. Manolov, V., Marinov, B., Vasilev, V., 2012. HE4 and CA125 in ovarian cancer. Akush. Ginekol. 51, 21-28.
15. NCCN: National Comprehensive Cancer Network, 2009. NCCN Practice Guidelines in Oncology: Ovarian cancer, Vol. 2.
16. Rustin, G.J.S., Nelstrop, A.E., Bentzen, S.M., Piccart, M.J., Bertelsen, K., 1999. Use of tumour markers in monitoring the course of ovarian cancer. Ann. Oncology. 10, 21-27.
17. Rustin, G.J.S., Nelstrop, A.E., Tuxen, M.K, Lambert, H.E., 1996. Defining progression of ovarian carcinoma during follow-up according to CA-125: A North Thames Ovary Group Study. Ann. Oncology. 7, 361-364.
18. Sproston, A.R.M., Roberts, S.A., Davidson, S.E., Hunter, R.D. , West, C.M.L., 1995. Serum tumor markers in carcinoma of the uterine cervix and outcome following radiotherapy. Brith. J. Cancer. 72,1536-1540.
19. Tietz, N.W. (Ed)., 1995. Clinical guide to laboratory tests, 3rd. ed. W. B. Saunders, Philadelphia, PA .pp.
20. Yin, B.W., Lloyd, K.O., 2001. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371-27375. Ali Omer et al.